Herantis Pharma participating at Alzheimer’s & Parkinson’s Drug Development Summit in Boston and Nordic Health Summit Japan.

Herantis Pharma Plc, Press Release 9 April 2024 at 09:00 EEST

Herantis Pharma Plc (“Herantis”), a clinical-stage biotechnology company developing disease modifying therapies for Parkinson’s disease is pleased to announce that Herantis management will participate at the virtual part of Nordic Health Summit Japan, April 25^th, and that Dr. Kira Holmström, Head of Biomarker Research at Herantis, has been selected to present at 12^th Alzheimer’s & Parkinson’s Drug Development Summit April 23-25^th in Boston.

The title and content of Dr. Holmström’s presentation is:

What can Parkinson’s Disease Learn from the Recent Progress in Alzheimer’s Disease? Lessons for HER-096.

• Learning from the recent Alzheimer’s Disease trial successes and how this can help inform PD treatment development, highlighting the importance of biomarkers.
• Understanding the importance of surrogate markers and development of clinical endpoints for a faster read on clinical trials.
• Pushing early biology and biomarker discovery to support clinical development, examples from HER-096.

For more information and to schedule a meeting, please contact us at ir@herantis.com.

About 12th Alzheimer’s & Parkinson’s Drug Development Summit:

The Alzheimer’s & Parkinson’s Summit is indisputably the ultimate industry-focused meeting dedicated to sharing the hottest unpublished AD & PD research from senior biopharma KOLs you won’t hear anywhere else, with deep-dive content all the way from early discovery through to late phase trials and approvals.

About Nordic Health Summit Japan 2024:

This is a partnering and investor conference that connects Nordic healthcare innovations and Japanese investors and industry. Nordic Health Summit Japan is co-hosted by Royal Danish Embassy in Tokyo, Business Finland Tokyo, Business Iceland Tokyo, Innovation Norway Tokyo, Business Sweden Tokyo, and Nordic Innovation House Tokyo.

For more information, please contact:

Tone Kvåle, CFO

Tel: +47 915 19576

Email: ir@herantis.com

Certified Advisor: UB Corporate Finance Oy, Finland: +358 9 25 380 225

About Herantis Pharma Plc

Herantis Pharma Plc is a clinical-stage biotechnology company developing disease modifying therapies for Parkinson’s disease. Herantis’ lead product HER-096, is an advanced small synthetic chemical peptidomimetic molecule developed based on the active site of the CDNF protein. It combines the compelling mechanism of action of CDNF with the convenience of subcutaneous administration. The Phase 1a clinical trial demonstrated a good safety and tolerability profile, and efficient blood-brain barrier penetration of subcutaneously administered HER-096 in humans. The shares of Herantis are listed on the Nasdaq First North Growth Market Finland.

Company website: www.herantis.com